Related Experiment Video
Updated: Mar 20, 2026
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in
James Keller1, Anjaruwee S Nimnual2, Mathew S Varghese2
1Division of Pediatric Hematology/Oncology, Stony Brook University, Stony Brook, New York.
Unlabelled:
EGFR is a popular therapeutic target for many cancers. EGFR inhibitors have been tested in children with refractory neuroblastoma. Interestingly, partial response or stable disease was observed in a few neuroblastoma patients. As EGFR mutations are biomarkers for response to anti-EGFR drugs, primary neuroblastoma tumors and cell lines were screened for mutations. A novel EGFR extracellular domain deletion mutant, EGFRΔ768, was discovered and the biologic and biochemical properties of this mutant were characterized and compared with wild-type and EGFRvIII receptors. EGFRΔ768 was found to be constitutively active and localized to the cell surface. Its expression conferred resistance to etoposide and drove proliferation as well as invasion of cancer cells. While EGFRΔ768 had similarity to EGFRvIII, its biologic and biochemical properties were distinctly different from both the EGFRvIII and wild-type receptors. Even though erlotinib inhibited EGFRΔ768, its effect on the mutant was not as strong as that on wild-type EGFR and EGFRvIII. In addition, downstream signaling of EGFRΔ768 was different from that of the wild-type receptor. In conclusion, this is the first study to demonstrate that neuroblastoma express not only EGFRvIII, but also a novel EGFR extracellular domain deletion mutant, EGFRΔ768. The EGFRΔ768 also possesses distinct biologic and biochemical properties which might have therapeutic implications for neuroblastoma as well as other tumors expressing this novel mutant.
Implications:
Neuroblastoma expressed a novel EGFR mutant which possesses distinct biologic and biochemical properties that might have therapeutic implications. Mol Cancer Res; 14(8); 740-52. ©2016 AACR.
Insights
Researchers discovered a new EGFR mutant, EGFRΔ768, in neuroblastoma. This mutant drives cancer growth and invasion, showing distinct properties that may impact future cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Epidermal Growth Factor Receptor (EGFR) is a key target in cancer therapy.
- EGFR inhibitors have shown limited efficacy in pediatric neuroblastoma.
- EGFR mutations serve as biomarkers for anti-EGFR drug response.
Purpose of the Study:
- To screen neuroblastoma tumors and cell lines for EGFR mutations.
- To characterize the biologic and biochemical properties of a novel EGFR mutant, EGFRΔ768.
- To compare EGFRΔ768 with wild-type EGFR and EGFRvIII.
Main Methods:
- Screening of primary neuroblastoma tumors and cell lines for EGFR mutations.
- Biochemical and biologic characterization of the novel EGFRΔ768 mutant.
- Comparative analysis of EGFRΔ768, wild-type EGFR, and EGFRvIII activity and signaling.
Main Results:
- Discovery of a novel EGFR extracellular domain deletion mutant, EGFRΔ768, in neuroblastoma.
- EGFRΔ768 exhibits constitutive activity, drives proliferation and invasion, and confers etoposide resistance.
- EGFRΔ768 shows distinct properties from wild-type EGFR and EGFRvIII, with partial sensitivity to erlotinib.
Conclusions:
- Neuroblastoma expresses both EGFRvIII and the novel mutant EGFRΔ768.
- EGFRΔ768 possesses unique biologic and biochemical characteristics.
- These findings suggest potential therapeutic implications for neuroblastoma and other cancers expressing EGFRΔ768.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:00Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...